Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

New cocktails to test limits of cancer drug pricing

New cancer drug cocktails set to reach the market in the next few years will test the limits of premium pricing for life-saving medicines, forcing company executives to consider fresh market strategies. The growing reluctance of governments and private insurers to fund very expensive drugs – even remarkably effective ones – points to a showdown […]

Read More »

Drinking Pear Juice Before A Booze-Filled Night May Prevent Your Hangover

Drinking pear juice before a night of heavy drinking could reduce the effects of a hangover, research suggests. Australian government scientists found that for those suffering the effects of the night before, the fruit significantly increased concentration. They also reduced memory loss and sensitivity to light and sound and even slightly decreased the alcohol levels […]

Read More »

Standing For Two Hours Of Your Day Found To Have Great Health Benefits, University of Queensland Study

If you can find time to stand at your desk every day, a new study says it dramatically improve your health. According to study leader Dr Genevieve Healy, senior research fellow at the University of Queensland, Australia: “We found that time spent standing rather than sitting was significantly associated with lower levels of blood sugar […]

Read More »

Spree Continues as Shire Snaps Up New York Eye Drop Developer for $300 Million

LEXINGTON, Massachusetts, August 3, 2015 /PRNewswire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million. With the acquisition, Shire acquires the global rights to FST-100 (topical ophthalmic drops combining 0.6% povidone iodine (PVP-I) and 0.1% dexamethasone), a therapy in late-stage development […]

Read More »

AstraZeneca PLC Pays Isis Pharma $65 Million Upfront in Antisense Drug Pact

August 3, 2015By Alex Keown, Breaking News Staff CARLSBAD, Calif. – Isis Pharmaceuticals, Inc. (ISIS) and AstraZeneca PLC (AZN) inked a deal to develop antisense therapies for cardiovascular, metabolic and renal diseases, the companies jointly announced this morning. This marks a continued trend for Isis to collaborate with a large pharmaceutical company to develop […]

Read More »

This Latest Study Adds One More Piece To The Alzheimer’s Puzzle

Alzheimer’s disease is believed to be caused by a buildup of beta-amyloid plaques in the brain, which interferes with neurons and disrupts cognitive function. More than 5 million people currently suffer from Alzheimer’s disease in the United States based on estimates from the Alzheimer’s Association; by 2050 close to 14 million people in the U.S. […]

Read More »

In A Story of Bribery, Sex Tapes, and Political Intrigue, GlaxoSmithKline Rehires Former Exec Linked to China Scandal

August 3, 2015By Mark Terry, Breaking News Staff U.K.-based GlaxoSmithKline (GSK) announced today that it had re-hired Vivian Shi. Shi was formerly a GSK government affairs executive linked to an internal investigation into alleged bribery accusations at the company’s China unit. In September 2014, a southern China court fined GSK almost $500 million on […]

Read More »

Pfizer Grabs Commercializatoin Rights of Potential MS Generic Treatment Glatiramer Acetate

Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis Synthon’s glatiramer acetate, a potential generic version of Copaxone®1 for the treatment of relapsing remitting multiple sclerosis is currently being reviewed by the U.S. Food and Drug Administration   NEW YORK & NIJMEGEN, Netherlands–(BUSINESS WIRE)– Pfizer Inc. and Synthon, an […]

Read More »

Brain-Controlled Prosthesis Nearly As Good As One-Finger Typing, Stanford University Reveals

When we type or perform other precise tasks, our brains and muscles usually work together effortlessly. But when a neurological disease or spinal cord injury severs the connection between the brain and limbs, once-easy motions become difficult or impossible. In recent years researchers have sought to give people suffering from injury or disease some restored […]

Read More »

Teva Announces Purchase Of 51% Equity Share Of Genomic-Analysis Company

Transaction underscores Teva’s “personalized-medicine” approach to treatment optimization across a spectrum of specialty and generics development programs and lifecycle management initiatives Teva gains exclusive rights to Immuneering’s cutting-edge analytics to advance treatments for diseases of the CNS   JERUSALEM & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and privately-held Immuneering Corporation today […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom